Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Rev Vaccines. 2006 Feb;5(1):45-54.

Extraintestinal isolates of Escherichia coli: identification and prospects for vaccine development.

Author information

1
Division of Infectious Diseases, Department of Medicine, University at Buffalo, Buffalo, NY 14214, USA. trusso@acsu.buffalo.edu

Abstract

Extraintestinal pathogenic Escherichia coli (ExPEC) cause a wide variety of infections that are responsible for significant morbidity, mortality and costs to our healthcare system. Thereby, the development of an efficacious ExPEC vaccine will minimize disease and may be cost-effective in selected patient groups. Surface polysaccharides, such as capsule, have been traditional targets for vaccine development. Considering that significant antigenic heterogeneity exists among surface polysaccharides present in various ExPEC strains, their use as vaccine candidates will be challenging. Therefore, alternative vaccine candidates/approaches are being identified and evaluated and are discussed in this review. The authors envision that an efficacious ExPEC vaccine will consist of either a polyvalent subunit vaccine or a genetically engineered killed whole-cell vaccine.

PMID:
16451107
DOI:
10.1586/14760584.5.1.45
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center